Skip to content
Menu

Kymera Therapeutics, Inc. KYMR

Full chart Compare
Set alert

Price alert · KYMR

All alert types
119.26 USD -1.87 (-1.54%)

As ofNov 19, 2026, 12:08 PM EST

117.65 Day range 122.47
63.69 52-week range 142.92
YTD
+53.27%
1 year
+83.99%

5D -15.03 (-11.01%)

120130WedThuFriMonTue121.52
Market cap
10.18B
Revenue (ttm)
102.23M
EPS (ttm)
-3.64
Shares out
85.37M
Forward P/E
-23.67
YTD return
+53.27%
1-year return
+83.99%
50-day average
117.40
200-day average
99.94
Enterprise value
9.48B
Volume
286.62K
Avg volume
838.12K
Open
121.00
Previous close
121.13
Day's range
117.65 – 122.47
52-week range
63.69 – 142.92
Beta
2.03
Analysts
Strong Buy
Price target
145.22 (+21.8%)
Earnings date
Feb 25, 2027

Key statistics

Price / sales
101.15
Price / book
6.40
Free cash flow
-164.68M
Total cash
971.21M
Total debt
76.60M
Return on equity
-27.29%
Short % of float
12.57%

Fundamental scorecard

5 of 25 checks passed on KYMR’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
KYMR Revenue — quarterly 0
KYMR Net income — quarterly -132.00M
KYMR EPS — quarterly -1.32

Earnings

KYMR recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 2026-1.29———
Oct 29, 2026Sep 30, 2026-1.26-1.32-0.06-4.76%
Aug 5, 2026Jun 30, 2026-0.7126-0.62+0.09+12.99%
Apr 30, 2026Mar 31, 2026-0.89-0.71+0.18+20.22%
Feb 26, 2026Dec 31, 2025-0.78366-0.97-0.19-23.78%
Nov 4, 2025Sep 30, 2025-0.71-0.90-0.19-26.76%

Upgrades / downgrades

KYMR analyst upgrades and downgrades
DateFirmActionFromTo
Nov 2, 2026BarclaysmainOverweightOverweight
Oct 30, 2026Truist SecuritiesreitBuyBuy
Oct 30, 2026RBC CapitalmainSector PerformSector Perform
Oct 29, 2026BTIGmainBuyBuy
Oct 27, 2026Morgan StanleymainOverweightOverweight
Oct 9, 2026Raymond Jamesinit—Outperform

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
kymeratx.com

News

Your note

Sign in to keep a note on KYMR — it syncs with the Stock Master app.

Insider holders

KYMR insider holders
InsiderRelationLatest transactionDateShares held
ADAMS BRIAN ROfficerSaleSep 3, 202650,254
BAKER BROS ADVISORS L.P.Beneficial Owner of more than 10% of a Class of SecurityPurchaseDec 10, 20250
BVF PARTNERS L PAffiliated PersonPurchaseJun 29, 20250
BVF PARTNERS L.P.Affiliated PersonSaleJun 25, 20260
CHADWICK JEREMY GChief Operating OfficerSaleMay 26, 202644,018
CHINIARA ELLEN VOfficerStock Award(Grant)Mar 2, 202580,085

Institution ownership

KYMR institution ownership
Holder% heldSharesValueReported
FMR, LLC14.72%12,568,9211.52BSep 29, 2026
Price (T.Rowe) Associates Inc10.22%8,725,9081.06BSep 29, 2026
Baker Bros. Advisors, LP10.14%8,657,2421.05BSep 29, 2026
Avoro Capital Advisors LLC8.76%7,474,747905.42MSep 29, 2026
Blackrock Inc.6.82%5,825,416705.63MSep 29, 2026
T. Rowe Price Investment Management, Inc.6.72%5,736,316694.84MSep 29, 2026

Fund ownership

KYMR fund ownership
Holder% heldSharesValueReported
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund2.67%2,279,147276.07MSep 29, 2026
T. Rowe Price New Horizons Fund, Inc.2.64%2,257,207273.42MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.45%2,089,249253.07MJun 29, 2026
T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App2.40%2,046,104247.84MJun 29, 2026
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund2.10%1,796,469217.61MJul 30, 2026
iShares Trust-iShares Russell 2000 ETF1.90%1,621,725196.44MSep 29, 2026